TG Therapeutics to Participate in the Evercore HealthCONx Conference

TGTX 11.29.2024

Full Press ReleaseSEC FilingsOur TGTX Tweets

About Gravity Analytica

Recent News

  • 01.14.2025 - TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue and 2025 Anticipated Development Milestones
  • 01.14.2025 - 43rd Annual J.P.Morgan Healthcare Conference
  • 01.09.2025 - TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

  • 01.14.2025 - 8-K Current report
  • 01.14.2025 - EX-99.1 EX-99.1
  • 01.08.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
PDF Version

Fireside chat scheduled for Tuesday, December 3, 2024, at 10:00 AM ET

NEW YORK, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the 7thAnnual Evercore HealthCONx Conference, being held at the Loews Coral Gables Hotel, in Florida on December 3-5, 2024. The fireside chat is scheduled to take place on Tuesday, December 3, at 10:00 AM ET.

A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website athttp://ir.tgtherapeutics.com/events.

ABOUT TG THERAPEUTICSTG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received U.S. Food and Drug Administration (FDA) approval for BRIUMVI®(ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features in Europe and the United Kingdom, respectively. For more information, visitwww.tgtherapeutics.com, and follow us on X (formerly Twitter)@TGTherapeuticsand onLinkedIn.

BRIUMVI®is a registered trademark of TG Therapeutics, Inc.

CONTACT:

Investor RelationsEmail: ir@tgtxinc.comTelephone: 1.877.575.TGTX (8489), Option 4

Media Relations:Email: media@tgtxinc.comTelephone: 1.877.575.TGTX (8489), Option 6

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com